Climb Bio (CLYM) Change in Cash (2020 - 2026)

Climb Bio (CLYM) has 7 years of Change in Cash data on file, last reported at -$27.3 million in Q1 2026.

• Quarterly Change in Cash rose 53.05% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.7 million (up 72.81% YoY) and the FY2025 annual result came in at -$51.5 million, down 776.15% from the prior year.
• Change in Cash declined to -$27.3 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $118.1 million in Q2 2024 to a low of -$77.0 million in Q3 2024.
• A 5-year average of -$2.3 million and a median of $671000.0 in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash plunged 1462.59% — and 2024, when it soared 1391.8%.
• Tracing CLYM's Change in Cash over 5 years: stood at $7.6 million in 2022, then soared by 367.99% to $35.8 million in 2023, then slumped by 264.84% to -$58.9 million in 2024, then soared by 116.76% to $9.9 million in 2025, then sank by 376.55% to -$27.3 million in 2026.
• The last three Change in Cash figures came in at -$27.3 million (Q1 2026), $9.9 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.